Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Hutchmed (China)
HCM
5
Lantheus
LNTH
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
Cost of revenue | ||||||||||
Gross profit | ||||||||||
Operating expense | 71.02%113.27M | 84.65%36.43M | 59.06%30.06M | 61.29%24.28M | 79.27%22.49M | 68.14%66.23M | 69.51%19.73M | 77.55%18.9M | 56.82%15.06M | 67.13%12.55M |
Selling and administrative expenses | 60.81%9.06M | 79.54%2.96M | 75.37%2.47M | 36.41%1.79M | 45.49%1.85M | 37.42%5.64M | 59.21%1.65M | 37.94%1.41M | 6.19%1.31M | 56.42%1.27M |
-General and administrative expense | 60.81%9.06M | 79.54%2.96M | 75.37%2.47M | 36.41%1.79M | 45.49%1.85M | 37.42%5.64M | 59.21%1.65M | 37.94%1.41M | 6.19%1.31M | 56.42%1.27M |
Research and development costs | 71.97%104.2M | 85.12%33.47M | 57.75%27.59M | 63.66%22.5M | 83.07%20.65M | 71.71%60.59M | 70.51%18.08M | 81.76%17.49M | 64.28%13.75M | 68.43%11.28M |
Operating profit | -71.02%-113.27M | -84.65%-36.43M | -59.06%-30.06M | -61.29%-24.28M | -79.27%-22.49M | -68.14%-66.23M | -69.51%-19.73M | -77.55%-18.9M | -56.82%-15.06M | -67.13%-12.55M |
Net non-operating interest income expense | -39.30%1.49M | -125.31%-222.91K | -45.67%268.11K | 19.98%561.27K | 44.70%881.38K | 350.39%2.45M | 1,422.35%880.8K | 297.27%493.5K | 230.02%467.8K | 242.70%609.12K |
Non-operating interest income | 51.31%11.77M | 33.99%3.05M | 93.61%3.61M | 58.28%2.82M | 23.28%2.28M | 590.02%7.78M | 209.58%2.28M | 548.93%1.87M | 1,763.95%1.78M | 22,588.22%1.85M |
Non-operating interest expense | 93.01%10.28M | 134.40%3.28M | 143.71%3.34M | 71.91%2.26M | 12.78%1.4M | 152.90%5.33M | 106.08%1.4M | 155.20%1.37M | 188.73%1.31M | 185.52%1.24M |
Other net income (expense) | ||||||||||
Income before tax | -75.26%-111.78M | -94.46%-36.65M | -61.87%-29.79M | -62.62%-23.72M | -81.03%-21.61M | -57.99%-63.78M | -62.75%-18.85M | -68.95%-18.4M | -46.45%-14.59M | -50.46%-11.94M |
Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income | -75.26%-111.78M | -94.46%-36.65M | -61.87%-29.79M | -62.62%-23.72M | -81.03%-21.61M | -57.99%-63.78M | -62.75%-18.85M | -68.95%-18.4M | -46.45%-14.59M | -50.46%-11.94M |
Net income continuous Operations | -75.26%-111.78M | -94.46%-36.65M | -61.87%-29.79M | -62.62%-23.72M | -81.03%-21.61M | -57.99%-63.78M | -62.75%-18.85M | -68.95%-18.4M | -46.45%-14.59M | -50.46%-11.94M |
Minority interest income | ||||||||||
Net income attributable to the parent company | -75.26%-111.78M | -94.46%-36.65M | -61.87%-29.79M | -62.62%-23.72M | -81.03%-21.61M | -57.99%-63.78M | -62.75%-18.85M | -68.95%-18.4M | -46.45%-14.59M | -50.46%-11.94M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -75.26%-111.78M | -94.46%-36.65M | -61.87%-29.79M | -62.62%-23.72M | -81.03%-21.61M | -57.99%-63.78M | -62.75%-18.85M | -68.95%-18.4M | -46.45%-14.59M | -50.46%-11.94M |
Basic earnings per share | -5.20%-2.83 | -32.81%-0.85 | 15.66%-0.7 | 6.06%-0.62 | -16.36%-0.64 | -1.89%-2.69 | 7.25%-0.64 | -10.67%-0.83 | 1.49%-0.66 | -3.77%-0.55 |
Diluted earnings per share | -5.20%-2.83 | -32.81%-0.85 | 15.66%-0.7 | 6.06%-0.62 | -16.36%-0.64 | -1.89%-2.69 | 7.25%-0.64 | -10.67%-0.83 | 1.49%-0.66 | -3.77%-0.55 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |